Form 4: Avid Bioservices Executive Exercises Stock Units

Mark R. Ziebell, V.P. and General Counsel of Avid Bioservices, Inc., reports the vesting and conversion of performance and restricted stock units.

Summary

• On July 9, 2024, Mark R. Ziebell, V.P. and General Counsel of Avid Bioservices, Inc., executed transactions involving performance stock units (PSUs) and restricted stock units (RSUs).
• 68,452 PSUs were converted, each representing the right to receive one share of Avid Bioservices' common stock.
• 34,226 RSUs were also converted, each representing the right to receive one share of Avid Bioservices' common stock.
• Following these transactions, Ziebell directly owns 142,797 shares resulting from PSU conversions and 69,092 shares resulting from RSU conversions.
• The PSUs vest based on Avid Bioservices achieving certain fiscal year revenue and adjusted pre-tax net income milestones over three fiscal years, starting April 30, 2025.
• The RSUs vest in sixteen equal quarterly installments over four years, beginning October 9, 2024.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to executive compensation. It doesn't contain any particularly positive or negative information, but the vesting of stock units tied to performance can be seen as a slightly positive sign.

Positives

• The vesting of PSUs is tied to the company's performance, specifically revenue and adjusted pre-tax net income milestones, aligning executive compensation with company success.

Risks

• The vesting of PSUs is contingent upon Avid Bioservices achieving specific financial milestones; failure to meet these targets will result in forfeiture of the corresponding portion of the PSUs.

Future Outlook

The vesting of PSUs is dependent on Avid Bioservices achieving certain fiscal year revenue and adjusted pre-tax net income milestones over three fiscal years.

Industry Context

This filing is a routine disclosure related to executive compensation in the biopharmaceutical contract development and manufacturing organization (CDMO) industry. It reflects standard practices for incentivizing key personnel through equity-based compensation.

Comparison to Industry Standards

• Equity-based compensation, including PSUs and RSUs, is a common practice among publicly traded companies in the biopharmaceutical and CDMO industries.
• Companies like Catalent, Lonza, and Thermo Fisher Scientific also utilize similar compensation structures to align executive interests with shareholder value.
• The specific vesting terms and performance metrics vary depending on the company's strategic goals and financial targets.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign, as it aligns executive compensation with the company's financial performance.
• Employees may be motivated by the fact that executive compensation is tied to the achievement of company milestones.

Key Dates

Keywords

Avid Bioservices, CDMO, Mark Ziebell, Form 4, Stock Units, PSU, RSU, Vesting, Executive Compensation